Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery.

Segall MD, Beresford AP, Gola JM, Hawksley D, Tarbit MH.

Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):325-37. Review.

PMID:
16866617
2.

In silico prediction of ADME properties: are we making progress?

Beresford AP, Segall M, Tarbit MH.

Curr Opin Drug Discov Devel. 2004 Jan;7(1):36-42. Review.

PMID:
14982146
3.

The emerging importance of predictive ADME simulation in drug discovery.

Selick HE, Beresford AP, Tarbit MH.

Drug Discov Today. 2002 Jan 15;7(2):109-16.

PMID:
11790621
4.

Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries.

Lewis DF, Dickins M, Eddershaw PJ, Tarbit MH, Goldfarb PS.

Drug Metabol Drug Interact. 1999;15(1):1-49. Review.

PMID:
10707112
6.

Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.

Lewis DF, Lake BG, George SG, Dickins M, Eddershaw PJ, Tarbit MH, Beresford AP, Goldfarb PS, Guengerich FP.

Toxicology. 1999 Nov 29;139(1-2):53-79.

PMID:
10614688
8.

Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity.

Lewis DF, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS.

Toxicology. 1999 Mar 1;133(1):1-33.

PMID:
10413191
10.

Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate.

Lewis DF, Eddershaw PJ, Dickins M, Tarbit MH, Goldfarb PS.

Chem Biol Interact. 1998 Oct 2;115(3):175-99. Review. Erratum in: Chem Biol Interact 1999 Jan 29;117(2):187.

PMID:
9851289
11.
12.
13.
14.

Genetic analysis of the human cytochrome P450 CYP2C9 locus.

Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR.

Pharmacogenetics. 1996 Oct;6(5):429-39.

PMID:
8946475
15.
16.

The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.

Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH.

Drug Metab Dispos. 1996 May;24(5):555-9.

PMID:
8723736
17.

Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans.

Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH.

Drug Metab Dispos. 1995 Nov;23(11):1225-30.

PMID:
8591723
18.
19.

Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver.

Dixon CM, Park GR, Tarbit MH.

Biochem Pharmacol. 1994 Mar 29;47(7):1253-7.

PMID:
8161354
20.

Applications of molecular biology and in vitro technology to drug metabolism studies: an industrial perspective.

Tarbit MH, Bayliss MK, Herriott D, Hood SR, Hutson JL, Park GR, Serabjit-Singh CJ.

Biochem Soc Trans. 1993 Nov;21(4):1018-23. Review. No abstract available.

PMID:
8131890
21.

Disposition of salmeterol xinafoate in laboratory animals and humans.

Manchee GR, Barrow A, Kulkarni S, Palmer E, Oxford J, Colthup PV, Maconochie JG, Tarbit MH.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1022-8.

PMID:
7905380
22.

Disposition of sumatriptan in laboratory animals and humans.

Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, Tarbit MH.

Drug Metab Dispos. 1993 Sep-Oct;21(5):761-9.

PMID:
7902233
23.
24.

The disposition and metabolism of [14C]fluconazole in humans.

Brammer KW, Coakley AJ, Jezequel SG, Tarbit MH.

Drug Metab Dispos. 1991 Jul-Aug;19(4):764-7.

PMID:
1680653
25.

Characterization of a quaternary, N-glucuronide metabolite of the imidazole antifungal, tioconazole.

Macrae PV, Kirrs M, Pullen FS, Tarbit MH.

Drug Metab Dispos. 1990 Nov-Dec;18(6):1100-2. No abstract available.

PMID:
1981520
26.

Discovery of fluconazole, a novel antifungal agent.

Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ.

Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S267-71. Review.

PMID:
2184503
28.

Comparison of two azole antifungal drugs, ketoconazole, and fluconazole, as modifiers of rat hepatic monooxygenase activity.

Houston JB, Humphrey MJ, Matthew DE, Tarbit MH.

Biochem Pharmacol. 1988 Feb 1;37(3):401-8.

PMID:
2827686
29.

In vitro potency and in vivo activity of azoles.

Troke PF, Marriott MS, Richardson K, Tarbit MH.

Ann N Y Acad Sci. 1988;544:284-93. No abstract available.

PMID:
3063173
30.

Design and evaluation of a systemically active agent, fluconazole.

Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ.

Ann N Y Acad Sci. 1988;544:4-11. No abstract available.

PMID:
2850752
31.

Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine.

Wood PR, Tarbit MH.

J Chromatogr. 1986 Nov 28;383(1):179-86. No abstract available.

PMID:
3029152
32.

Treatment of cryptococcal meningitis in mice with fluconazole.

Palou de Fernandez E, Patino MM, Graybill JR, Tarbit MH.

J Antimicrob Chemother. 1986 Aug;18(2):261-70.

PMID:
3019986
33.

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Humphrey MJ, Jevons S, Tarbit MH.

Antimicrob Agents Chemother. 1985 Nov;28(5):648-53.

34.

Tioconazole, a new imidazole-antifungal agent for the treatment of dermatomycoses. Antifungal and pharmacologic properties.

Marriott MS, Baird JR, Brammer KW, Faulkner JK, Halliwell G, Jevons S, Tarbit MH.

Dermatologica. 1983;166 Suppl 1:1-7.

PMID:
6884559
35.

Tioconazole, a new broad-spectrum antifungal agent: preclinical studies related to vaginal candidiasis.

Marriott MS, Brammer KW, Faccini J, Faulkner JK, Jevons S, Monro AM, Nachbaur J, Perraud J, Tarbit MH.

Gynakol Rundsch. 1983;23 Suppl 1:1-11. No abstract available.

PMID:
6683696
36.

The pattern of intramural veins of the left ventricle of the human heart.

Farrer-Brown G, Tarbit MH.

Br Heart J. 1975 Jan;37(1):85-93.

37.

The vascular pattern of the left ventricle of normal hearts from East Africans in Uganda.

Farrer-Brown G, Tarbit MH.

Afr J Med Sci. 1973 Oct;4(4):419-33. No abstract available.

PMID:
4792057
38.
39.

Microvascular study of hearts with endomyocardial fibrosis.

Farrer-Brown G, Tarbit MH, Somers K, Hutt MS.

Br Heart J. 1972 Dec;34(12):1250-62. No abstract available.

40.

The microvasculature of heart valves in rheumatic heart disease.

Farrer-Brown G, Tarbit MH.

Am Heart J. 1972 Nov;84(5):610-9. No abstract available.

PMID:
4639734
41.

Heart valve involvement in endomyocardial fibrosis.

Farrer-Brown G, Tarbit MH.

Br Heart J. 1972 Oct;34(10):1062-71. No abstract available.

42.

What is the spectrum of endomyocardial fibrosis?

Farrer-Brown G, Tarbit MH.

Trop Geogr Med. 1972 Sep;24(3):208-18. No abstract available.

PMID:
4636093
43.

The vascularisation of rheumatic heart valves.

Farrer-Brown G, Tarbit MH.

J Pathol. 1972 Jan;106(1):Pi. No abstract available.

PMID:
5035749
44.

Venous changes in the endometrium of myomatous uteri.

Farrer-Brown G, Beilby JO, Tarbit MH.

Obstet Gynecol. 1971 Nov;38(5):743-51. No abstract available.

PMID:
5114225
45.

The microvasculature of common uterine abnormalities, other than fibroids.

Beilby JO, Farrer-Brown G, Tarbit MH.

J Obstet Gynaecol Br Commonw. 1971 Apr;78(4):361-8. No abstract available.

PMID:
5558320
46.

The microvasculature of the uterus.

Farrer-Brown G, Beilby JO, Tarbit MH.

J Pathol. 1971 Feb;103(2):Pvi-vii. No abstract available.

PMID:
5567939
47.

The vascular patterns in myomatous uteri.

Farrer-Brown G, Beilby JO, Tarbit MH.

J Obstet Gynaecol Br Commonw. 1970 Nov;77(11):967-75. No abstract available.

PMID:
5483419
48.

The blood supply of the uterus. 2. Venous pattern.

Farrer-Brown G, Beilby JO, Tarbit MH.

J Obstet Gynaecol Br Commonw. 1970 Aug;77(8):682-9. No abstract available.

PMID:
5452129
49.

The blood supply of the uterus. 1. Arterial vasculature.

Farrer-Brown G, Beilby JO, Tarbit MH.

J Obstet Gynaecol Br Commonw. 1970 Aug;77(8):673-81. No abstract available.

PMID:
5452128
50.

Formation and loss of DNA in intestinal epithelium.

Appleton TC, Pelc SR, Tarbit MH.

J Cell Sci. 1969 Jul;5(1):45-55. No abstract available.

Supplemental Content

Loading ...
Support Center